MENLO PARK, Calif., June 25, 2014 /PRNewswire/ -- Virobay, Inc., a clinical stage pharmaceutical company with a broad platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune diseases and fibrosis, today announced the appointment of James Welch as Chief Financial Officer, effective as of June 20, 2014.
Mr. Welch has more than 20 years of experience in financial and operational management at life science and high technology firms. Prior to joining Virobay, Mr. Welch was Chief Financial Officer at AcelRx Pharmaceuticals, a publicly held pharmaceutical company dedicated to the development and commercialization of innovative products for the treatment of painful conditions. Previously, Mr. Welch was Chief Financial Officer at Cerimon Pharmaceuticals, a privately held pharmaceutical company focusing on developing pain and autoimmune disease products. Before Cerimon, Mr. Welch was Chief Financial Officer at Rigel Pharmaceuticals. Earlier in his career, Mr. Welch was Chief Financial Officer of Biocircuits Corporation, a publicly held medical diagnostic company, and held various financial and operational management positions at technology firms in Silicon Valley, including NeXT Computer and Avantek.
"I am delighted to have Jim join Virobay," commented Dr. Robert Booth, President and Chief Executive Officer of Virobay. "Jim has an outstanding track record and breadth of experience in capital fund raising, strategic planning and investor relations for both private and public biotechnology companies. Jim's depth of experience in both senior financial positions and in corporate operational roles is well suited to help Virobay pursue our clinical and business objectives."
"Utilizing its expertise in cysteine cathepsins as a platform, Virobay has the opportunity to help treat neuropathic pain, autoimmune diseases and fibrosis," stated Mr. Welch. "I am thrilled to join the Virobay team."
Virobay is focused on the development and commercialization of novel drugs through the utilization of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases, for a variety of conditions, including neuropathic pain, autoimmune diseases and fibrosis. The foundation of Virobay's proprietary cathepsin platform and the Virobay management team were spun-out from Celera Genomics, which was then a leader in cathepsin research. Virobay's clinical pipeline currently includes product candidates in neuropathic pain, dermatology, autoimmune disease and fibrosis. For more information please visit our website: www.virobayinc.com.
Chief Financial Officer
SOURCE Virobay, Inc.